TABLE 3.

Performance of CSF Phospho-Tau as a Biomarker for Alzheimer’s Disease

Study Number	P-tau Epitope	Number of AD Cases	AD Sensitivity	Number of Controls	Controls Specificity	Comment	Ref.
1	P-Thr181	80	84	40	88		92
2	P-Thr181	41	44	17	95		70
3	P-Thr181	19	58	17	94		52
4	P-Thr181	108	85	23	91	Two-center study	93
5	P-Thr181	51	84	31	84		94
6	P-Thr181	42	88	43	100		26
7	P-Thr181	18	89	13	85		95
8	P-Ser199	36	94	20	80	“Non-AD” controls	22
9	P-Ser199	236	85	95	n.g.	Multicenter	86
10	P-Ser199	108	85	23	82	Two-center study	93
11	P-Thr231	27	85	31	97	“Non-AD” controls	23
12	P-Thr231	82	100	21	91		71
13	P-Thr231	108	85	23	96	Two-center study	93
14	P-Thr181 + P-Thr231	40	88	31	97		14
15	P-Thr231 + P-Ser235	36	53	20	100	“Non-AD” controls	22
16	P-Ser396+404	52	94	56	89	Cut-off P-tau > 100 pg/mL	24
Total		1084	81.3	504	91.2

n.g. = not given.